When Kinases Meet PROTACs-Reference-Cited by-同舟云学术

When Kinases Meet PROTACs

Published:2018-08-28 Issue:10 Volume:36 Page:971-977
ISSN:1001-604X
Container-title:Chinese Journal of Chemistry
language:en
Short-container-title:Chin. J. Chem.

Author:

Tan Li¹,Gray Nathanael S.²³

Affiliation:

1. Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry; Chinese Academy of Sciences; 26 Qiuyue Rd, Pudong, Shanghai 201210 China

2. Department of Cancer Biology; Dana-Farber Cancer Institute; Boston MA 02215 USA

3. Department of Biochemistry and Molecular Pharmacology; Harvard Medical School; Boston MA 02115 USA

Publisher

Wiley

Subject

General Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cjoc.201800293/fullpdf

Reference41 articles.

1. http://www.centerwatch.com/drug-information/fda-approved-drugs/

2. FDA-approved small-molecule kinase inhibitors

3. Advances and challenges in targeting FGFR signalling in cancer

4. Structural Basis for the Non-catalytic Functions of Protein Kinases

5. Kinase inhibitors: the road ahead

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue;Chemical Biology & Drug Design;2024-04

2. Degradation of Polo-like Kinase 1 by the Novel Poly-Arginine N-Degron Pathway PROTAC Regulates Tumor Growth in Nonsmall Cell Lung Cancer;Journal of Medicinal Chemistry;2023-12-17

3. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies;Molecules;2023-05-10

4. Progress of small molecules for targeted protein degradation: PROTACs and other technologies;Drug Development Research;2023-01-06

5. PROTACting the kinome with covalent warheads;Drug Discovery Today;2023-01